A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer
ConditionProstate Cancer
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexMale
Age18+
SponsorMatrix Biomed, Inc.
About this trial
A single patient compassionate use clinical trial for the use of MBM-02 (TEMPOL) for the treatment of prostate cancer. The single patient will be exposed to orally administered TEMPOL for up to 12 months at a maximum total daily dose of 800mg.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Biochemical Recurrent Prostate Cancer
Disqualifiers
None
Trial design
Treatments tested in this trial
MBM-02 (Tempol)
DrugStudy drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
Treatment groups
No treatment groups listed
Trial outcomes
This trial has no outcomes listed.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov